Global Pneumonia Vaccine Market

Pneumonia Vaccine Comprehensive Study by Type (Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23)), Patient Type (Pediatric Patients, Adult Patients), Distribution Channel (Clinics, Hospitals, Others) Players and Region - Global Market Outlook to 2027

Pneumonia Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Pneumonia is a lung infection which occurs in one or both the lungs caused by bacteria, fungi or viruses. Bacterial pneumonia is the common form occurring in adults. Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, that results in filling the alveoli with fluid, so causing breathing problems. This disease is common in young children, older adults are at high risk of severe pneumococcal infections and even death. Growing prevalence of pneumonia across the globe, increasing government focus on immunization programs for pneumonia, as well as introduction of novel pneumococcal vaccines such as PCV10 are the factors that drive growth of global Pneumonia Vaccine market. Pneumonia Vaccine such as Pneumococcal Conjugate Vaccine (PCV13), and Pneumococcal Polysaccharide Vaccine (PPSV23) are used for treatment of Pneumonia.This growth is primarily driven by Rising Government Involvement in Design & Implementation of Comprehensive Vaccination Programs .

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Volume UnitK Units
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Pfizer Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Merck & Co., Inc. (United States), Sanofi Pasteur (France), Serum Institute of India Private Limited (India), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent Biosolutions, Inc. (United States), Biological E limited (India) and Panacea Drugs Pvt. Ltd. (India), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.



Regulatory Insights:
“In United States, The Center for Disease Control and Prevention (CDC), a leading national public health institute recommends yearly influenza vaccination for every person 6 months and older. Immunizing health care workers decreases the risk of viral pneumonia among their patients. CDC recommends pneumococcal vaccination for all children younger than 2 years old and all adults 65 years or older. In certain situations, other children and adults should also get pneumococcal vaccines.”

Market Growth Drivers:
Rising Government Involvement in Design & Implementation of Comprehensive Vaccination Programs, Increasing Prevalence of Pneumonia Infection among People and Growing Awareness Regarding Pneumonia Vaccine

Challenges:
Insufficient Access to Vaccines

Restraints:
High Cost of Vaccine Development

Opportunities:
High Growth Prospects in Emerging Markets and Advancement of Protein-Based Combination Pneumococcal Vaccines

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Pneumonia Vaccine Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Pneumonia Vaccine Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Pneumonia Vaccine players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Pneumonia Vaccine Study Sheds Light on
— The Pneumonia Vaccine Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Pneumonia Vaccine industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Pneumonia Vaccine industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Pneumococcal Conjugate Vaccine (PCV13)
  • Pneumococcal Polysaccharide Vaccine (PPSV23)
By Patient Type
  • Pediatric Patients
  • Adult Patients

By Distribution Channel
  • Clinics
  • Hospitals
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Government Involvement in Design & Implementation of Comprehensive Vaccination Programs
      • 3.2.2. Increasing Prevalence of Pneumonia Infection among People
      • 3.2.3. Growing Awareness Regarding Pneumonia Vaccine
    • 3.3. Market Challenges
      • 3.3.1. Insufficient Access to Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pneumonia Vaccine, by Type, Patient Type, Distribution Channel and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Pneumonia Vaccine (Value)
      • 5.2.1. Global Pneumonia Vaccine by: Type (Value)
        • 5.2.1.1. Pneumococcal Conjugate Vaccine (PCV13)
        • 5.2.1.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
      • 5.2.2. Global Pneumonia Vaccine by: Patient Type (Value)
        • 5.2.2.1. Pediatric Patients
        • 5.2.2.2. Adult Patients
      • 5.2.3. Global Pneumonia Vaccine by: Distribution Channel (Value)
        • 5.2.3.1. Clinics
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Others
      • 5.2.4. Global Pneumonia Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Pneumonia Vaccine (Volume)
      • 5.3.1. Global Pneumonia Vaccine by: Type (Volume)
        • 5.3.1.1. Pneumococcal Conjugate Vaccine (PCV13)
        • 5.3.1.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
      • 5.3.2. Global Pneumonia Vaccine by: Patient Type (Volume)
        • 5.3.2.1. Pediatric Patients
        • 5.3.2.2. Adult Patients
      • 5.3.3. Global Pneumonia Vaccine by: Distribution Channel (Volume)
        • 5.3.3.1. Clinics
        • 5.3.3.2. Hospitals
        • 5.3.3.3. Others
      • 5.3.4. Global Pneumonia Vaccine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Pneumonia Vaccine (Price)
      • 5.4.1. Global Pneumonia Vaccine by: Type (Price)
  • 6. Pneumonia Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi Pasteur (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Serum Institute of India Private Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Astellas Pharma Inc. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CSL Limited (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Emergent Biosolutions, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biological E limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Panacea Drugs Pvt. Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pneumonia Vaccine Sale, by Type, Patient Type, Distribution Channel and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Pneumonia Vaccine (Value)
      • 7.2.1. Global Pneumonia Vaccine by: Type (Value)
        • 7.2.1.1. Pneumococcal Conjugate Vaccine (PCV13)
        • 7.2.1.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
      • 7.2.2. Global Pneumonia Vaccine by: Patient Type (Value)
        • 7.2.2.1. Pediatric Patients
        • 7.2.2.2. Adult Patients
      • 7.2.3. Global Pneumonia Vaccine by: Distribution Channel (Value)
        • 7.2.3.1. Clinics
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Others
      • 7.2.4. Global Pneumonia Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Pneumonia Vaccine (Volume)
      • 7.3.1. Global Pneumonia Vaccine by: Type (Volume)
        • 7.3.1.1. Pneumococcal Conjugate Vaccine (PCV13)
        • 7.3.1.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
      • 7.3.2. Global Pneumonia Vaccine by: Patient Type (Volume)
        • 7.3.2.1. Pediatric Patients
        • 7.3.2.2. Adult Patients
      • 7.3.3. Global Pneumonia Vaccine by: Distribution Channel (Volume)
        • 7.3.3.1. Clinics
        • 7.3.3.2. Hospitals
        • 7.3.3.3. Others
      • 7.3.4. Global Pneumonia Vaccine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Pneumonia Vaccine (Price)
      • 7.4.1. Global Pneumonia Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pneumonia Vaccine: by Type(USD Million)
  • Table 2. Pneumonia Vaccine Pneumococcal Conjugate Vaccine (PCV13) , by Region USD Million (2016-2021)
  • Table 3. Pneumonia Vaccine Pneumococcal Polysaccharide Vaccine (PPSV23) , by Region USD Million (2016-2021)
  • Table 4. Pneumonia Vaccine: by Patient Type(USD Million)
  • Table 5. Pneumonia Vaccine Pediatric Patients , by Region USD Million (2016-2021)
  • Table 6. Pneumonia Vaccine Adult Patients , by Region USD Million (2016-2021)
  • Table 7. Pneumonia Vaccine: by Distribution Channel(USD Million)
  • Table 8. Pneumonia Vaccine Clinics , by Region USD Million (2016-2021)
  • Table 9. Pneumonia Vaccine Hospitals , by Region USD Million (2016-2021)
  • Table 10. Pneumonia Vaccine Others , by Region USD Million (2016-2021)
  • Table 11. South America Pneumonia Vaccine, by Country USD Million (2016-2021)
  • Table 12. South America Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 13. South America Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 14. South America Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 15. Brazil Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 16. Brazil Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 17. Brazil Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 18. Argentina Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 19. Argentina Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 20. Argentina Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 21. Rest of South America Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 22. Rest of South America Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 23. Rest of South America Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 24. Asia Pacific Pneumonia Vaccine, by Country USD Million (2016-2021)
  • Table 25. Asia Pacific Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 26. Asia Pacific Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 27. Asia Pacific Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 28. China Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 29. China Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 30. China Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 31. Japan Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 32. Japan Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 33. Japan Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 34. India Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 35. India Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 36. India Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 37. South Korea Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 38. South Korea Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 39. South Korea Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 40. Taiwan Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 41. Taiwan Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 42. Taiwan Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 43. Australia Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 44. Australia Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 45. Australia Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 49. Europe Pneumonia Vaccine, by Country USD Million (2016-2021)
  • Table 50. Europe Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 51. Europe Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 52. Europe Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 53. Germany Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 54. Germany Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 55. Germany Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 56. France Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 57. France Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 58. France Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 59. Italy Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 60. Italy Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 61. Italy Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 62. United Kingdom Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 63. United Kingdom Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 64. United Kingdom Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 65. Netherlands Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 66. Netherlands Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 67. Netherlands Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 68. Rest of Europe Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 69. Rest of Europe Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 70. Rest of Europe Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 71. MEA Pneumonia Vaccine, by Country USD Million (2016-2021)
  • Table 72. MEA Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 73. MEA Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 74. MEA Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 75. Middle East Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 76. Middle East Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 77. Middle East Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 78. Africa Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 79. Africa Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 80. Africa Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 81. North America Pneumonia Vaccine, by Country USD Million (2016-2021)
  • Table 82. North America Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 83. North America Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 84. North America Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 85. United States Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 86. United States Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 87. United States Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 88. Canada Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 89. Canada Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 90. Canada Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 91. Mexico Pneumonia Vaccine, by Type USD Million (2016-2021)
  • Table 92. Mexico Pneumonia Vaccine, by Patient Type USD Million (2016-2021)
  • Table 93. Mexico Pneumonia Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 94. Pneumonia Vaccine Sales: by Type(K Units)
  • Table 95. Pneumonia Vaccine Sales Pneumococcal Conjugate Vaccine (PCV13) , by Region K Units (2016-2021)
  • Table 96. Pneumonia Vaccine Sales Pneumococcal Polysaccharide Vaccine (PPSV23) , by Region K Units (2016-2021)
  • Table 97. Pneumonia Vaccine Sales: by Patient Type(K Units)
  • Table 98. Pneumonia Vaccine Sales Pediatric Patients , by Region K Units (2016-2021)
  • Table 99. Pneumonia Vaccine Sales Adult Patients , by Region K Units (2016-2021)
  • Table 100. Pneumonia Vaccine Sales: by Distribution Channel(K Units)
  • Table 101. Pneumonia Vaccine Sales Clinics , by Region K Units (2016-2021)
  • Table 102. Pneumonia Vaccine Sales Hospitals , by Region K Units (2016-2021)
  • Table 103. Pneumonia Vaccine Sales Others , by Region K Units (2016-2021)
  • Table 104. South America Pneumonia Vaccine Sales, by Country K Units (2016-2021)
  • Table 105. South America Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 106. South America Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 107. South America Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 108. Brazil Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 109. Brazil Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 110. Brazil Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 111. Argentina Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 112. Argentina Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 113. Argentina Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 114. Rest of South America Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 115. Rest of South America Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 116. Rest of South America Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 117. Asia Pacific Pneumonia Vaccine Sales, by Country K Units (2016-2021)
  • Table 118. Asia Pacific Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 119. Asia Pacific Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 120. Asia Pacific Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 121. China Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 122. China Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 123. China Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 124. Japan Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 125. Japan Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 126. Japan Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 127. India Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 128. India Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 129. India Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 130. South Korea Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 131. South Korea Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 132. South Korea Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 133. Taiwan Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 134. Taiwan Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 135. Taiwan Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 136. Australia Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 137. Australia Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 138. Australia Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 139. Rest of Asia-Pacific Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 140. Rest of Asia-Pacific Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 141. Rest of Asia-Pacific Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 142. Europe Pneumonia Vaccine Sales, by Country K Units (2016-2021)
  • Table 143. Europe Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 144. Europe Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 145. Europe Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 146. Germany Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 147. Germany Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 148. Germany Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 149. France Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 150. France Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 151. France Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 152. Italy Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 153. Italy Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 154. Italy Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 155. United Kingdom Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 156. United Kingdom Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 157. United Kingdom Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 158. Netherlands Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 159. Netherlands Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 160. Netherlands Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 161. Rest of Europe Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 162. Rest of Europe Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 163. Rest of Europe Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 164. MEA Pneumonia Vaccine Sales, by Country K Units (2016-2021)
  • Table 165. MEA Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 166. MEA Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 167. MEA Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 168. Middle East Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 169. Middle East Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 170. Middle East Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 171. Africa Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 172. Africa Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 173. Africa Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 174. North America Pneumonia Vaccine Sales, by Country K Units (2016-2021)
  • Table 175. North America Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 176. North America Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 177. North America Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 178. United States Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 179. United States Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 180. United States Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 181. Canada Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 182. Canada Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 183. Canada Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 184. Mexico Pneumonia Vaccine Sales, by Type K Units (2016-2021)
  • Table 185. Mexico Pneumonia Vaccine Sales, by Patient Type K Units (2016-2021)
  • Table 186. Mexico Pneumonia Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 187. Pneumonia Vaccine: by Type(USD/Units)
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Pneumonia Vaccine: by Type(USD Million)
  • Table 199. Pneumonia Vaccine Pneumococcal Conjugate Vaccine (PCV13) , by Region USD Million (2022-2027)
  • Table 200. Pneumonia Vaccine Pneumococcal Polysaccharide Vaccine (PPSV23) , by Region USD Million (2022-2027)
  • Table 201. Pneumonia Vaccine: by Patient Type(USD Million)
  • Table 202. Pneumonia Vaccine Pediatric Patients , by Region USD Million (2022-2027)
  • Table 203. Pneumonia Vaccine Adult Patients , by Region USD Million (2022-2027)
  • Table 204. Pneumonia Vaccine: by Distribution Channel(USD Million)
  • Table 205. Pneumonia Vaccine Clinics , by Region USD Million (2022-2027)
  • Table 206. Pneumonia Vaccine Hospitals , by Region USD Million (2022-2027)
  • Table 207. Pneumonia Vaccine Others , by Region USD Million (2022-2027)
  • Table 208. South America Pneumonia Vaccine, by Country USD Million (2022-2027)
  • Table 209. South America Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 210. South America Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 211. South America Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 212. Brazil Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 213. Brazil Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 214. Brazil Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 215. Argentina Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 216. Argentina Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 217. Argentina Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 218. Rest of South America Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 219. Rest of South America Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 220. Rest of South America Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 221. Asia Pacific Pneumonia Vaccine, by Country USD Million (2022-2027)
  • Table 222. Asia Pacific Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 223. Asia Pacific Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 224. Asia Pacific Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 225. China Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 226. China Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 227. China Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 228. Japan Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 229. Japan Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 230. Japan Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 231. India Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 232. India Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 233. India Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 234. South Korea Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 235. South Korea Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 236. South Korea Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 237. Taiwan Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 238. Taiwan Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 239. Taiwan Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 240. Australia Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 241. Australia Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 242. Australia Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 243. Rest of Asia-Pacific Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 244. Rest of Asia-Pacific Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 245. Rest of Asia-Pacific Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 246. Europe Pneumonia Vaccine, by Country USD Million (2022-2027)
  • Table 247. Europe Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 248. Europe Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 249. Europe Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 250. Germany Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 251. Germany Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 252. Germany Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 253. France Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 254. France Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 255. France Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 256. Italy Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 257. Italy Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 258. Italy Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 259. United Kingdom Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 260. United Kingdom Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 261. United Kingdom Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 262. Netherlands Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 263. Netherlands Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 264. Netherlands Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 265. Rest of Europe Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 266. Rest of Europe Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 267. Rest of Europe Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 268. MEA Pneumonia Vaccine, by Country USD Million (2022-2027)
  • Table 269. MEA Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 270. MEA Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 271. MEA Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 272. Middle East Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 273. Middle East Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 274. Middle East Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 275. Africa Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 276. Africa Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 277. Africa Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 278. North America Pneumonia Vaccine, by Country USD Million (2022-2027)
  • Table 279. North America Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 280. North America Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 281. North America Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 282. United States Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 283. United States Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 284. United States Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 285. Canada Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 286. Canada Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 287. Canada Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 288. Mexico Pneumonia Vaccine, by Type USD Million (2022-2027)
  • Table 289. Mexico Pneumonia Vaccine, by Patient Type USD Million (2022-2027)
  • Table 290. Mexico Pneumonia Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 291. Pneumonia Vaccine Sales: by Type(K Units)
  • Table 292. Pneumonia Vaccine Sales Pneumococcal Conjugate Vaccine (PCV13) , by Region K Units (2022-2027)
  • Table 293. Pneumonia Vaccine Sales Pneumococcal Polysaccharide Vaccine (PPSV23) , by Region K Units (2022-2027)
  • Table 294. Pneumonia Vaccine Sales: by Patient Type(K Units)
  • Table 295. Pneumonia Vaccine Sales Pediatric Patients , by Region K Units (2022-2027)
  • Table 296. Pneumonia Vaccine Sales Adult Patients , by Region K Units (2022-2027)
  • Table 297. Pneumonia Vaccine Sales: by Distribution Channel(K Units)
  • Table 298. Pneumonia Vaccine Sales Clinics , by Region K Units (2022-2027)
  • Table 299. Pneumonia Vaccine Sales Hospitals , by Region K Units (2022-2027)
  • Table 300. Pneumonia Vaccine Sales Others , by Region K Units (2022-2027)
  • Table 301. South America Pneumonia Vaccine Sales, by Country K Units (2022-2027)
  • Table 302. South America Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 303. South America Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 304. South America Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 305. Brazil Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 306. Brazil Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 307. Brazil Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 308. Argentina Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 309. Argentina Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 310. Argentina Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 311. Rest of South America Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 312. Rest of South America Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 313. Rest of South America Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 314. Asia Pacific Pneumonia Vaccine Sales, by Country K Units (2022-2027)
  • Table 315. Asia Pacific Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 316. Asia Pacific Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 317. Asia Pacific Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 318. China Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 319. China Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 320. China Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 321. Japan Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 322. Japan Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 323. Japan Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 324. India Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 325. India Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 326. India Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 327. South Korea Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 328. South Korea Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 329. South Korea Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 330. Taiwan Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 331. Taiwan Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 332. Taiwan Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 333. Australia Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 334. Australia Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 335. Australia Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 336. Rest of Asia-Pacific Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 337. Rest of Asia-Pacific Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 338. Rest of Asia-Pacific Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 339. Europe Pneumonia Vaccine Sales, by Country K Units (2022-2027)
  • Table 340. Europe Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 341. Europe Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 342. Europe Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 343. Germany Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 344. Germany Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 345. Germany Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 346. France Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 347. France Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 348. France Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 349. Italy Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 350. Italy Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 351. Italy Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 352. United Kingdom Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 353. United Kingdom Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 354. United Kingdom Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 355. Netherlands Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 356. Netherlands Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 357. Netherlands Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 358. Rest of Europe Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 359. Rest of Europe Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 360. Rest of Europe Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 361. MEA Pneumonia Vaccine Sales, by Country K Units (2022-2027)
  • Table 362. MEA Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 363. MEA Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 364. MEA Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 365. Middle East Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 366. Middle East Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 367. Middle East Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 368. Africa Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 369. Africa Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 370. Africa Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 371. North America Pneumonia Vaccine Sales, by Country K Units (2022-2027)
  • Table 372. North America Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 373. North America Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 374. North America Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 375. United States Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 376. United States Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 377. United States Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 378. Canada Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 379. Canada Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 380. Canada Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 381. Mexico Pneumonia Vaccine Sales, by Type K Units (2022-2027)
  • Table 382. Mexico Pneumonia Vaccine Sales, by Patient Type K Units (2022-2027)
  • Table 383. Mexico Pneumonia Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 384. Pneumonia Vaccine: by Type(USD/Units)
  • Table 385. Research Programs/Design for This Report
  • Table 386. Key Data Information from Secondary Sources
  • Table 387. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pneumonia Vaccine: by Type USD Million (2016-2021)
  • Figure 5. Global Pneumonia Vaccine: by Patient Type USD Million (2016-2021)
  • Figure 6. Global Pneumonia Vaccine: by Distribution Channel USD Million (2016-2021)
  • Figure 7. South America Pneumonia Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Pneumonia Vaccine Share (%), by Country
  • Figure 9. Europe Pneumonia Vaccine Share (%), by Country
  • Figure 10. MEA Pneumonia Vaccine Share (%), by Country
  • Figure 11. North America Pneumonia Vaccine Share (%), by Country
  • Figure 12. Global Pneumonia Vaccine: by Type K Units (2016-2021)
  • Figure 13. Global Pneumonia Vaccine: by Patient Type K Units (2016-2021)
  • Figure 14. Global Pneumonia Vaccine: by Distribution Channel K Units (2016-2021)
  • Figure 15. South America Pneumonia Vaccine Share (%), by Country
  • Figure 16. Asia Pacific Pneumonia Vaccine Share (%), by Country
  • Figure 17. Europe Pneumonia Vaccine Share (%), by Country
  • Figure 18. MEA Pneumonia Vaccine Share (%), by Country
  • Figure 19. North America Pneumonia Vaccine Share (%), by Country
  • Figure 20. Global Pneumonia Vaccine: by Type USD/Units (2016-2021)
  • Figure 21. Global Pneumonia Vaccine share by Players 2021 (%)
  • Figure 22. Global Pneumonia Vaccine share by Players (Top 3) 2021(%)
  • Figure 23. Global Pneumonia Vaccine share by Players (Top 5) 2021(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 27. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2021
  • Figure 29. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co., Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi Pasteur (France) Revenue: by Geography 2021
  • Figure 33. Serum Institute of India Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Serum Institute of India Private Limited (India) Revenue: by Geography 2021
  • Figure 35. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Astellas Pharma Inc. (Japan) Revenue: by Geography 2021
  • Figure 37. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 38. CSL Limited (Australia) Revenue: by Geography 2021
  • Figure 39. Emergent Biosolutions, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Emergent Biosolutions, Inc. (United States) Revenue: by Geography 2021
  • Figure 41. Biological E limited (India) Revenue, Net Income and Gross profit
  • Figure 42. Biological E limited (India) Revenue: by Geography 2021
  • Figure 43. Panacea Drugs Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 44. Panacea Drugs Pvt. Ltd. (India) Revenue: by Geography 2021
  • Figure 45. Global Pneumonia Vaccine: by Type USD Million (2022-2027)
  • Figure 46. Global Pneumonia Vaccine: by Patient Type USD Million (2022-2027)
  • Figure 47. Global Pneumonia Vaccine: by Distribution Channel USD Million (2022-2027)
  • Figure 48. South America Pneumonia Vaccine Share (%), by Country
  • Figure 49. Asia Pacific Pneumonia Vaccine Share (%), by Country
  • Figure 50. Europe Pneumonia Vaccine Share (%), by Country
  • Figure 51. MEA Pneumonia Vaccine Share (%), by Country
  • Figure 52. North America Pneumonia Vaccine Share (%), by Country
  • Figure 53. Global Pneumonia Vaccine: by Type K Units (2022-2027)
  • Figure 54. Global Pneumonia Vaccine: by Patient Type K Units (2022-2027)
  • Figure 55. Global Pneumonia Vaccine: by Distribution Channel K Units (2022-2027)
  • Figure 56. South America Pneumonia Vaccine Share (%), by Country
  • Figure 57. Asia Pacific Pneumonia Vaccine Share (%), by Country
  • Figure 58. Europe Pneumonia Vaccine Share (%), by Country
  • Figure 59. MEA Pneumonia Vaccine Share (%), by Country
  • Figure 60. North America Pneumonia Vaccine Share (%), by Country
  • Figure 61. Global Pneumonia Vaccine: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • GlaxoSmithKline plc. (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Sanofi Pasteur (France)
  • Serum Institute of India Private Limited (India)
  • Astellas Pharma Inc. (Japan)
  • CSL Limited (Australia)
  • Emergent Biosolutions, Inc. (United States)
  • Biological E limited (India)
  • Panacea Drugs Pvt. Ltd. (India)
Select User Access Type

Key Highlights of Report


Jun 2023 231 Pages 76 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pneumonia Vaccine Market Quantitative research analysis
Global Pneumonia Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Pneumonia Vaccine Market are Pfizer Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Merck & Co., Inc. (United States), Sanofi Pasteur (France), Serum Institute of India Private Limited (India), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent Biosolutions, Inc. (United States), Biological E limited (India) and Panacea Drugs Pvt. Ltd. (India) etc.
AMA Research predicts that Japanese, Indian, French, and United States Players will contribute to the maximum growth of Global Pneumonia Vaccine market throughout the forecasted period.

Know More About Global Pneumonia Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Scopolamine Comprehensive Study by Type (Scopolamine Butylbromide, Scopolamine Hydrobromide, Scopolamine Base), Application (Oral, Injection, Patches), Form (Tablet, Syrup), Distribution Channel (Hos...
$ 3650
Pharmaceutical Lab Equipment Comprehensive Study by Type (General instrument, Analytical instrument, Specialty instrument, Others), Application (Research Institutions, Academic laboratory, Pharmaceut...
$ 3450
Interferon Comprehensive Study by Application (Oncology, Autoimmune Disorders, Diabetes, Inflammatory and Infectious Diseases, Neurological Diseases, Cardiovascular Diseases, Others), Drug Type (Inte...
$ 3750
Phytosterols Comprehensive Study by Type (Beta-Sitosterol, Campesterol, Stigmasterol, Others), Application (Dairy Products, Beverages, Sauces and Condiments, Bakery and Confectionery, Pharmaceutical,...
$ 3500
Steroids Comprehensive Study by Type (Corticosteroids, Anabolic), Application (Health care products, Daily diet, Hospital, Clinic, Others), Distribution Channel (Online Retail, Offline Retail), For...
$ 3500
Analgesics Comprehensive Study by Type (Opioid Alkaloids Analgesics {Morphina, Codeine, Other}, Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other}), Application (Nervous System, Digestive ...
$ 3750